Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease

To identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease. This study included 23 patients (46 eyes) with acute-phase VKHdivided into two subgroups: Group 1; acute-resolved (10 patients), group 2; chronic-recurrent (13 patients). Mean age were 29.5 ± 10.2 years in group 1, 35.8 ± 12.2...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2023-09, Vol.ahead-of-print (ahead-of-print), p.1-7
Main Authors: Kaya, Pınar, İnanç Tekin, Merve, Özdal, Pınar Çakar
Format: Article
Language:English
Subjects:
Optical coherence tomography
predictive factor
prognosis
uveitis
Vogt-Koyanagi-Harada disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c366t-77e03f890aa8e1da4597f5a3f9122ce6b399d4f3e8c179abb47432ae180f26cc3
cites cdi_FETCH-LOGICAL-c366t-77e03f890aa8e1da4597f5a3f9122ce6b399d4f3e8c179abb47432ae180f26cc3
container_end_page 7
container_issue ahead-of-print
container_start_page 1
container_title Ocular immunology and inflammation
container_volume ahead-of-print
creator Kaya, Pınar
İnanç Tekin, Merve
Özdal, Pınar Çakar
description To identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease. This study included 23 patients (46 eyes) with acute-phase VKHdivided into two subgroups: Group 1; acute-resolved (10 patients), group 2; chronic-recurrent (13 patients). Mean age were 29.5 ± 10.2 years in group 1, 35.8 ± 12.2 years group 2 (p = .033). Best-corrected visual acuity with logMAR at admission was 0.91 ± 0.65 in group 1, 0.88 ± 0.62 in group 2 (p = .798), and improved to 0.08 ± 0.24, 0.18 ± 0.6, respectively (p = .557). Extraocular findings were detected in 30% in group 1, and 53.8% in group 2 at the time of admission (p = .108). All patients were treated with 1 g/day 3-5 days intravenous steroid, and 10 patients had immunomodulatory treatment. Initiation of immunomodulatory therapy did not affect the prognosis (p = .676). Older patients and/or who developed extraocular findings at the presentation were more prone to show recurrences.
doi_str_mv 10.1080/09273948.2022.2159841
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2764443417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2764443417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-77e03f890aa8e1da4597f5a3f9122ce6b399d4f3e8c179abb47432ae180f26cc3</originalsourceid><addsrcrecordid>eNp9kM1OAjEURhujEUQfQTNLN4P9m2m704iIkUQW6ra5dFqsGabYDhre3iGAS1d3c757koPQJcFDgiW-wYoKprgcUkzpkJJCSU6OUJ8IzvMCC3mM-lsm30I9dJbSJ8aYK0VOUY-VJZWclX00mkVbedP6b5uNwbQhpsyFmLUfNpvFsGhC8ikLLnsPizZ_DhtoYOHzCUSoIBv5ZCHZc3TioE72Yn8H6G388Ho_yacvj0_3d9PcdMI2F8Ji5qTCANKSCnihhCuAOUUoNbacM6Uq7piVhggF8zkXnFGwRGJHS2PYAF3v_q5i-Frb1OqlT8bWNTQ2rJOmouScM05EhxY71MSQUrROr6JfQtxogvU2oD4E1NuAeh-w213tFev50lZ_q0OxDrjdAb7pOi3hJ8S60i1s6hBdhMb4pNn_jl9P1H7R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2764443417</pqid></control><display><type>article</type><title>Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Kaya, Pınar ; İnanç Tekin, Merve ; Özdal, Pınar Çakar</creator><creatorcontrib>Kaya, Pınar ; İnanç Tekin, Merve ; Özdal, Pınar Çakar</creatorcontrib><description>To identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease. This study included 23 patients (46 eyes) with acute-phase VKHdivided into two subgroups: Group 1; acute-resolved (10 patients), group 2; chronic-recurrent (13 patients). Mean age were 29.5 ± 10.2 years in group 1, 35.8 ± 12.2 years group 2 (p = .033). Best-corrected visual acuity with logMAR at admission was 0.91 ± 0.65 in group 1, 0.88 ± 0.62 in group 2 (p = .798), and improved to 0.08 ± 0.24, 0.18 ± 0.6, respectively (p = .557). Extraocular findings were detected in 30% in group 1, and 53.8% in group 2 at the time of admission (p = .108). All patients were treated with 1 g/day 3-5 days intravenous steroid, and 10 patients had immunomodulatory treatment. Initiation of immunomodulatory therapy did not affect the prognosis (p = .676). Older patients and/or who developed extraocular findings at the presentation were more prone to show recurrences.</description><identifier>ISSN: 0927-3948</identifier><identifier>EISSN: 1744-5078</identifier><identifier>DOI: 10.1080/09273948.2022.2159841</identifier><identifier>PMID: 36628436</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Optical coherence tomography ; predictive factor ; prognosis ; uveitis ; Vogt-Koyanagi-Harada disease</subject><ispartof>Ocular immunology and inflammation, 2023-09, Vol.ahead-of-print (ahead-of-print), p.1-7</ispartof><rights>2023 Taylor &amp; Francis Group, LLC 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-77e03f890aa8e1da4597f5a3f9122ce6b399d4f3e8c179abb47432ae180f26cc3</citedby><cites>FETCH-LOGICAL-c366t-77e03f890aa8e1da4597f5a3f9122ce6b399d4f3e8c179abb47432ae180f26cc3</cites><orcidid>0000-0002-9930-7680 ; 0000-0002-5714-7172</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36628436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaya, Pınar</creatorcontrib><creatorcontrib>İnanç Tekin, Merve</creatorcontrib><creatorcontrib>Özdal, Pınar Çakar</creatorcontrib><title>Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease</title><title>Ocular immunology and inflammation</title><addtitle>Ocul Immunol Inflamm</addtitle><description>To identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease. This study included 23 patients (46 eyes) with acute-phase VKHdivided into two subgroups: Group 1; acute-resolved (10 patients), group 2; chronic-recurrent (13 patients). Mean age were 29.5 ± 10.2 years in group 1, 35.8 ± 12.2 years group 2 (p = .033). Best-corrected visual acuity with logMAR at admission was 0.91 ± 0.65 in group 1, 0.88 ± 0.62 in group 2 (p = .798), and improved to 0.08 ± 0.24, 0.18 ± 0.6, respectively (p = .557). Extraocular findings were detected in 30% in group 1, and 53.8% in group 2 at the time of admission (p = .108). All patients were treated with 1 g/day 3-5 days intravenous steroid, and 10 patients had immunomodulatory treatment. Initiation of immunomodulatory therapy did not affect the prognosis (p = .676). Older patients and/or who developed extraocular findings at the presentation were more prone to show recurrences.</description><subject>Optical coherence tomography</subject><subject>predictive factor</subject><subject>prognosis</subject><subject>uveitis</subject><subject>Vogt-Koyanagi-Harada disease</subject><issn>0927-3948</issn><issn>1744-5078</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OAjEURhujEUQfQTNLN4P9m2m704iIkUQW6ra5dFqsGabYDhre3iGAS1d3c757koPQJcFDgiW-wYoKprgcUkzpkJJCSU6OUJ8IzvMCC3mM-lsm30I9dJbSJ8aYK0VOUY-VJZWclX00mkVbedP6b5uNwbQhpsyFmLUfNpvFsGhC8ikLLnsPizZ_DhtoYOHzCUSoIBv5ZCHZc3TioE72Yn8H6G388Ho_yacvj0_3d9PcdMI2F8Ji5qTCANKSCnihhCuAOUUoNbacM6Uq7piVhggF8zkXnFGwRGJHS2PYAF3v_q5i-Frb1OqlT8bWNTQ2rJOmouScM05EhxY71MSQUrROr6JfQtxogvU2oD4E1NuAeh-w213tFev50lZ_q0OxDrjdAb7pOi3hJ8S60i1s6hBdhMb4pNn_jl9P1H7R</recordid><startdate>20230914</startdate><enddate>20230914</enddate><creator>Kaya, Pınar</creator><creator>İnanç Tekin, Merve</creator><creator>Özdal, Pınar Çakar</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9930-7680</orcidid><orcidid>https://orcid.org/0000-0002-5714-7172</orcidid></search><sort><creationdate>20230914</creationdate><title>Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease</title><author>Kaya, Pınar ; İnanç Tekin, Merve ; Özdal, Pınar Çakar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-77e03f890aa8e1da4597f5a3f9122ce6b399d4f3e8c179abb47432ae180f26cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Optical coherence tomography</topic><topic>predictive factor</topic><topic>prognosis</topic><topic>uveitis</topic><topic>Vogt-Koyanagi-Harada disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaya, Pınar</creatorcontrib><creatorcontrib>İnanç Tekin, Merve</creatorcontrib><creatorcontrib>Özdal, Pınar Çakar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ocular immunology and inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaya, Pınar</au><au>İnanç Tekin, Merve</au><au>Özdal, Pınar Çakar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease</atitle><jtitle>Ocular immunology and inflammation</jtitle><addtitle>Ocul Immunol Inflamm</addtitle><date>2023-09-14</date><risdate>2023</risdate><volume>ahead-of-print</volume><issue>ahead-of-print</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>0927-3948</issn><eissn>1744-5078</eissn><abstract>To identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease. This study included 23 patients (46 eyes) with acute-phase VKHdivided into two subgroups: Group 1; acute-resolved (10 patients), group 2; chronic-recurrent (13 patients). Mean age were 29.5 ± 10.2 years in group 1, 35.8 ± 12.2 years group 2 (p = .033). Best-corrected visual acuity with logMAR at admission was 0.91 ± 0.65 in group 1, 0.88 ± 0.62 in group 2 (p = .798), and improved to 0.08 ± 0.24, 0.18 ± 0.6, respectively (p = .557). Extraocular findings were detected in 30% in group 1, and 53.8% in group 2 at the time of admission (p = .108). All patients were treated with 1 g/day 3-5 days intravenous steroid, and 10 patients had immunomodulatory treatment. Initiation of immunomodulatory therapy did not affect the prognosis (p = .676). Older patients and/or who developed extraocular findings at the presentation were more prone to show recurrences.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>36628436</pmid><doi>10.1080/09273948.2022.2159841</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9930-7680</orcidid><orcidid>https://orcid.org/0000-0002-5714-7172</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0927-3948
ispartof Ocular immunology and inflammation, 2023-09, Vol.ahead-of-print (ahead-of-print), p.1-7
issn 0927-3948
1744-5078
language eng
recordid cdi_proquest_miscellaneous_2764443417
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Optical coherence tomography
predictive factor
prognosis
uveitis
Vogt-Koyanagi-Harada disease
title Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A07%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20Factors%20for%20the%20Prognosis%20of%20Vogt-Koyanagi-Harada%20Disease&rft.jtitle=Ocular%20immunology%20and%20inflammation&rft.au=Kaya,%20P%C4%B1nar&rft.date=2023-09-14&rft.volume=ahead-of-print&rft.issue=ahead-of-print&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=0927-3948&rft.eissn=1744-5078&rft_id=info:doi/10.1080/09273948.2022.2159841&rft_dat=%3Cproquest_pubme%3E2764443417%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-77e03f890aa8e1da4597f5a3f9122ce6b399d4f3e8c179abb47432ae180f26cc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2764443417&rft_id=info:pmid/36628436&rfr_iscdi=true